Abstract:PURPOSE The way late-onset toxicities are managed can affect trial outcomes and participant safety. Specifically, participants often might not have completed their entire follow-up period to observe any toxicities before new participants would be recruited. We conducted a methodological review of published early-phase dose-finding clinical trials that used designs accounting for partial and complete toxicity information, aiming to understand (1) how such designs were implemented and reported and (2) if sufficient information was provided to enable the replicability of trial results. METHODS Until March 26, 2023, we identified 141 trials using the rolling 6 design, the time-to-event continuous reassessment method (TITE-CRM), the TITE-CRM with cycle information, the TITE Bayesian optimal interval design, the TITE cumulative cohort design, and the rapid enrollment design. Clinical settings, design parameters, practical considerations, and dose-limiting toxicity (DLT) information were extracted from these published trials. RESULTS The TITE-CRM (61, 43.3%) and the rolling 6 design (76, 53.9%) were most frequently implemented in practice. Trials using the TITE-CRM had longer DLT assessment windows beyond the first cycle compared with the rolling 6 design (52.5% v 6.6%). Most trials implementing the TITE-CRM (91.8%, 56 of 61) failed to describe essential parameters in the protocols or the study result papers. Only five TITE-CRM trials (8.2%, 5 of 61) reported sufficient information to enable replication of the final analysis. CONCLUSION When compared with trials using the rolling 6 design, those implementing the TITE-CRM design exhibited notable deficiencies in reporting essential details necessary for reproducibility. Inadequate reporting quality of advanced model-based trial designs hinders their credibility. We provide recommendations that can improve transparency, reproducibility, and accurate interpretation of the results for such designs.

Joint TITE-CRM: A Design for Dose Finding Studies for Therapies with Late-Onset Safety and Activity Outcomes

Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials

TITE‐BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose with Late‐onset Toxicity and Efficacy

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Dose Finding Studies for Therapies with Late-Onset Toxicities: A Comparison Study of Designs

MT-Keyboard: A Bayesian Model-assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials

Robust EM Continual Reassessment Method in Oncology Dose Finding

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

Utpi: A Utility‐based Toxicity Probability Interval Design for Phase I/II Dose‐finding Trials

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Gboin: a Unified Model-Assisted Phase I Trial Design Accounting for Toxicity Grades, and Binary or Continuous End Points

Statistical Tutorial for Using Bayesian Optimal Interval (BOIN) Design for Phase I Single-Agent and Drug-Combination Trials

Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Incorporating Historical Information to Improve Phase I Clinical Trials

Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

MC-Keyboard: A Practical Phase I Trial Design for Targeted Therapies and Immunotherapies Integrating Multiple-Grade Toxicities

Bayesian Interval-Based Oncology Dose-Finding Design with Repeated Quasi-Continuous Toxicity Model